Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Cyclosporin A
55
CHF
CHF 55.00
In stock
AG-CN2-0079-M100100 mgCHF 55.00
AG-CN2-0079-51005 x 100 mgCHF 165.00
AG-CN2-0079-G0011 gCHF 190.00
| Product Details | |
|---|---|
| Synonyms | Antibiotic S 7481F1; Ciclosporin A; CsA; Cyclosporine; NSC 290193; Ramihyphin A |
| Product Type | Chemical |
| Properties | |
| Formula |
C62H111N11O12 |
| MW | 1202.6 |
| Merck Index | 14: 2752 |
| CAS | 59865-13-3 |
| RTECS | GZ4120000 |
| Source/Host Chemicals | Isolated from Tolypocladium inflatum. |
| Purity Chemicals | ≥98% |
| Appearance | White solid. |
| Solubility | Soluble in DMSO, ethanol, methanol, dichlormethane, chloroform or acetone. Insoluble in water. |
| InChi Key | PMATZTZNYRCHOR-VPYFBNRVBI |
| Smiles | [H][C@@]1([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC1=O)C(C)C |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 3 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Potent immunosuppressant (same as FK-506 (Prod. No. AG-CN2-0047) and rapamycin (Prod. No. AG-CN2-0025)).
- Forms a complex with cyclophilin. Inhibits the activity of the calcium/calmodulin-dependent protein phosphatase 2B (PP2B; calcineurin). Prevents the dephosphorylation of nuclear factor of activated T cells (NFAT) transcription factor, leading to disruption of T cell activation.
- Suppresses proliferation of cytotoxic T cells and inhibits the production of T cell-derived mediators such as interleukin-2 (IL-2).
- Prevents rejection of transplanted organs.
- Anti-inflammatory compound in the treatment of several inflammatory skin diseases (e.g. atopic dermatitis) and with potential anti-rheumatic activity (rheumatoid arthritis).
- Antibacterial. Antifungal. Antiparasitic.
- Apoptosis inhibitor. Inhibits the mitochondrial permeability transition pore (MPTP) from opening, thus inhibiting cytochrome c release.
- NF-κB suppressor by induction of unfolded protein response (UPR).
- Anti-cancer compound. Apoptosis and autophagy inducer.
- Inhibits nitric oxide synthesis induced by interleukin-1α, lipopolysaccharides and TNF-α.
- Potently induces highly cardiogenic progenitors from embryonic stem (ES) cells.
Product References
- Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A: D.A. Fruman, et al.; PNAS 89, 3686 (1992)
- Cyclosporin A, FK506 and rapamycin: more than just immunosuppression: J. Kunz & M.N. Hall; TIBS 18, 334 (1993)
- Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology: B.E. Bierer, et al.; Curr. Opin. Immunol. 5, 763 (1993)
- Immunological actions of cyclosporin A in rheumatoid arthritis: D. Yocum; Br. J. Rheumatol. 32, 38 (1993)
- The antimicrobial activities of cyclosporine, FK506, and rapamycin: H.P. High; Tansplantation 57, 1689 (1994) (Review)
- Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2: A.R. Gottschalk, et al.; PNAS 91, 7350 (1994)
- Inhibition of the mitochondrial permeability transition pore by cyclosporin A during long time frame experiments: relationship between pore opening and the activity of mitochondrial phospholipases. K.M. Broekemeier & D.R. Pfeiffer; Biochemistry 34, 16440 (1995)
- Effects of cyclosporin A and FK506 on nitric oxide and tetrahydrobiopterin synthesis in bacterial lipopolysaccharide-treated J774 macrophages: Y. Hattori & N. Naranishi; Cell Immunol. 165, 7 (1995)
- Inhibition of T lymphocyte activation and apoptotic cell death by cyclosporin A and tacrolimus (FK506). Its relevance to therapy of HIV infection: A.W. Thomson & C.A. Bonham; Adv. Exp. Med. Biol. 374, 211 (1995) (Review)
- FK506 in the treatment of inflammatory skin disease: promises and perspectives: G. Michel, et al.; Immunol. Today 17, 106 (1996) (Review)
- The antiparasite effects of cyclosporin A: possible drug targets and clinical applications: A. Bell, et al.; Gen. Pharmacol. 27, 963 (1996) (Review)
- The mechanism of action of cyclosporin A and FK506: S. Ho, et al.; Clin. Immunol. Immunopathol. 80, S40 (1996) (Review)
- Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus: K.A. Jorgensen, et al.; Scand. J. Immunol. 57, 93 (2003) (Review)
- Suppression of NF-kappaB by cyclosporin A and tacrolimus (FK506) via induction of the C/EBP family: implication for unfolded protein response: S. Du, et al.; J. Immunol. 182, 7201 (2009)
- Melatonin suppresses cyclosporine A-induced autophagy in rat pituitary GH3 cells: Y.M. Yoo & E.B. Jeung; J. Pineal Res. 48, 204 (2010)
- Cyclosporin-A potently induces highly cardiogenic progenitors from embryonic stem cells: P. Yan, et al.; BBRC 379, 115 (2009)
Related Products
